<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00314821</url>
  </required_header>
  <id_info>
    <org_study_id>CHA-IRB-0116/05/05</org_study_id>
    <nct_id>NCT00314821</nct_id>
  </id_info>
  <brief_title>Ropinirole in the Treatment of Bipolar Depression</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study of the Efficacy of Ropinirole in the Treatment of Depression in Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge Health Alliance</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge Health Alliance</source>
  <brief_summary>
    <textblock>
      To demonstrate efficacy and safety of Requip in in treating bipolar depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is 8 weeks long, with an optional additional 8 weeks. The study is
      placebo-controlled and patients are randomized to receive either ropinerol or placebo.
      Changes in depression, anxiety and overall psychiatric symptoms will be monitored during
      participation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2005</start_date>
  <completion_date type="Actual">March 17, 2008</completion_date>
  <primary_completion_date type="Actual">June 1, 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome will be group differences between Requip and placebo in random effects linear regression analysis.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary outcomes will include predictors of response, such as insight into illness, comorbid anxiety symptoms, prior course of illness, previous treatment history with antidepressants, and other relevant clinical and demographic features.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bipolar Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ropinirole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet DSM-IV criteria for bipolar disorder

          -  Current MADRS score &gt; 16

          -  Current MRS-SADS score &lt; 10

          -  Prior to participation in this study, each subject must sign an informed consent.

          -  All patients will be required to also take at least one other mood-stabilizing agent,
             defined as a standard agent (lithium, valproate, carbamazepine) or a novel
             anticonvulsant agent (oxcarbazepine, gabapentin, topiramate). If patients are not
             taking any of these agents on study initiation, they will be required to start one of
             these agents at study initiation. Study inclusion criteria must be met after at least
             2 weeks of treatment with one of these mood-stabilizing agents.

        Exclusion Criteria:

          -  Any serious acute medical illness

          -  Any clinically serious evidence of suicidality or score of 3 or greater on suicide
             item on MADRS scale
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert T Dunn, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cambridge Health Alliance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge Health Alliance</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2006</study_first_submitted>
  <study_first_submitted_qc>April 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2006</study_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bipolar disorder, ropinirole, depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropinirole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

